Companies sponsors |
EQRx (aumolertinib) |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
EGFR Positive UK |
|
Roy Castle Lung Cancer Foundation |
Professional groups |
Association of Cancer Physicians |
|
British Thoracic Society |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Comparator companies |
• Accord Healthcare (gefitinib) (confidentiality agreement not signed, not participating) |
|
• AstraZeneca (gefitinib, osimertinib) |
|
• Boehringer Ingelheim (afatinib) (confidentiality agreement not signed, not participating) |
|
• Cipla EU (gefitinib) (confidentiality agreement not signed, not participating) |
|
• Genus Pharmaceuticals (gefitinib) (confidentiality agreement not signed, not participating) |
|
• Glenmark Pharmaceuticals Europe (erlotinib, gefitinib) (confidentiality agreement not signed, not participating) |
|
• Mylan (erlotinib) (confidentiality agreement not signed, not participating) |
|
• Pfizer (dacomitinib) |
|
• Roche (erlotinib) (confidentiality agreement not signed, not participating) |
|
• Sandoz (erlotinib, gefitinib) (confidentiality agreement not signed, not participating) (confidentiality agreement not signed, not participating) |
|
• Tillomed Laboratories (erlotinib) (confidentiality agreement not signed, not participating) |
|
• Zentiva (erlotinib, gefitinib) (confidentiality agreement not signed, not participating) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |